TRML
TRML
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $25.974M ▼ | $-23.092M ▼ | 0% | $-0.9 ▼ | $-25.974M ▲ |
| Q1-2025 | $0 ▼ | $26.231M ▲ | $-22.97M ▼ | 0% ▲ | $-0.89 ▼ | $-26.231M ▼ |
| Q4-2024 | $40K ▲ | $25.816M ▲ | $-22.235M ▼ | -55.587K% ▼ | $-0.86 ▼ | $-25.836M ▼ |
| Q3-2024 | $0 | $24.438M ▲ | $-20.177M ▼ | 0% | $-0.78 ▼ | $-24.428M ▼ |
| Q2-2024 | $0 | $21.961M | $-17.487M | 0% | $-0.68 | $-21.971M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $239.234M ▼ | $269.295M ▼ | $10.103M ▲ | $259.192M ▼ |
| Q1-2025 | $249.306M ▼ | $287.498M ▼ | $7.635M ▼ | $279.863M ▼ |
| Q4-2024 | $258.303M ▼ | $309.001M ▼ | $8.949M ▲ | $300.052M ▼ |
| Q3-2024 | $281.924M ▼ | $328.447M ▼ | $7.379M ▲ | $321.068M ▼ |
| Q2-2024 | $289.533M | $344.791M | $6.509M | $338.282M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-23.092M ▼ | $-20.264M ▲ | $16.303M ▼ | $54K ▼ | $-3.907M ▼ | $-20.271M ▲ |
| Q1-2025 | $-22.97M ▼ | $-21.679M ▼ | $25.941M ▲ | $562K ▲ | $4.824M ▲ | $-21.688M ▼ |
| Q4-2024 | $-22.235M ▼ | $-20.889M ▲ | $16.39M ▲ | $-3K ▼ | $-4.502M ▲ | $-20.898M ▲ |
| Q3-2024 | $-20.177M ▼ | $-23.444M ▼ | $-11.695M ▼ | $-1K ▼ | $-35.14M ▼ | $-23.444M ▼ |
| Q2-2024 | $-17.487M | $-18.007M | $-10.131M | $0 | $-28.138M | $-18.007M |
About Tourmaline Bio, Inc.
https://www.tourmalinebio.comTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $25.974M ▼ | $-23.092M ▼ | 0% | $-0.9 ▼ | $-25.974M ▲ |
| Q1-2025 | $0 ▼ | $26.231M ▲ | $-22.97M ▼ | 0% ▲ | $-0.89 ▼ | $-26.231M ▼ |
| Q4-2024 | $40K ▲ | $25.816M ▲ | $-22.235M ▼ | -55.587K% ▼ | $-0.86 ▼ | $-25.836M ▼ |
| Q3-2024 | $0 | $24.438M ▲ | $-20.177M ▼ | 0% | $-0.78 ▼ | $-24.428M ▼ |
| Q2-2024 | $0 | $21.961M | $-17.487M | 0% | $-0.68 | $-21.971M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $239.234M ▼ | $269.295M ▼ | $10.103M ▲ | $259.192M ▼ |
| Q1-2025 | $249.306M ▼ | $287.498M ▼ | $7.635M ▼ | $279.863M ▼ |
| Q4-2024 | $258.303M ▼ | $309.001M ▼ | $8.949M ▲ | $300.052M ▼ |
| Q3-2024 | $281.924M ▼ | $328.447M ▼ | $7.379M ▲ | $321.068M ▼ |
| Q2-2024 | $289.533M | $344.791M | $6.509M | $338.282M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-23.092M ▼ | $-20.264M ▲ | $16.303M ▼ | $54K ▼ | $-3.907M ▼ | $-20.271M ▲ |
| Q1-2025 | $-22.97M ▼ | $-21.679M ▼ | $25.941M ▲ | $562K ▲ | $4.824M ▲ | $-21.688M ▼ |
| Q4-2024 | $-22.235M ▼ | $-20.889M ▲ | $16.39M ▲ | $-3K ▼ | $-4.502M ▲ | $-20.898M ▲ |
| Q3-2024 | $-20.177M ▼ | $-23.444M ▼ | $-11.695M ▼ | $-1K ▼ | $-35.14M ▼ | $-23.444M ▼ |
| Q2-2024 | $-17.487M | $-18.007M | $-10.131M | $0 | $-28.138M | $-18.007M |
CEO
Sandeep C. Kulkarni
Compensation Summary
(Year 2024)
CEO
Sandeep C. Kulkarni
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-10-20 | Reverse | 1:10 |
Most Recent Analyst Grades
BMO Capital
Market Perform
LifeSci Capital
Market Perform
Piper Sandler
Neutral
HC Wainwright & Co.
Neutral
Guggenheim
Neutral
Chardan Capital
Neutral
Wedbush
Neutral
Truist Securities
Hold
Jefferies
Hold
Grade Summary
Price Target
Institutional Ownership
AVORO CAPITAL ADVISORS LLC
2.556M Shares
$122.616M
QVT FINANCIAL LP
2.155M Shares
$103.38M
BLACKROCK INC.
1.724M Shares
$82.728M
BLACKROCK, INC.
1.518M Shares
$72.823M
TCG CROSSOVER MANAGEMENT, LLC
1.312M Shares
$62.939M
PFIZER INC
1.272M Shares
$61.041M
VANGUARD GROUP INC
1.166M Shares
$55.926M
FIL LTD
1.028M Shares
$49.309M
MAGNETAR FINANCIAL LLC
966.129K Shares
$46.355M
QIMING U.S. VENTURES MANAGEMENT, LLC
741.691K Shares
$35.586M
FIRST TRUST CAPITAL MANAGEMENT L.P.
695.757K Shares
$33.382M
PICTET ASSET MANAGEMENT HOLDING SA
682.129K Shares
$32.729M
TIG ADVISORS, LLC
619.763K Shares
$29.736M
VIVO CAPITAL, LLC
591.882K Shares
$28.398M
ALLIANCEBERNSTEIN L.P.
539.961K Shares
$25.907M
NEXPOINT ASSET MANAGEMENT, L.P.
455.36K Shares
$21.848M
GEODE CAPITAL MANAGEMENT, LLC
453.952K Shares
$21.781M
STATE STREET CORP
415.97K Shares
$19.958M
GOLDMAN SACHS GROUP INC
376.738K Shares
$18.076M
AQR ARBITRAGE LLC
374.785K Shares
$17.982M
Summary
Only Showing The Top 20